Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?

Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic ac...

Full description

Bibliographic Details
Main Authors: Wang, Z., Chen, C., Finger, S., Kwajah, M., Jung, M., Schwarz, H., Swanson, N., Lareu, Ricardo, Raghunath, M.
Format: Journal Article
Published: European Respiratory Society 2009
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/34604
_version_ 1848754268037709824
author Wang, Z.
Chen, C.
Finger, S.
Kwajah, M.
Jung, M.
Schwarz, H.
Swanson, N.
Lareu, Ricardo
Raghunath, M.
author_facet Wang, Z.
Chen, C.
Finger, S.
Kwajah, M.
Jung, M.
Schwarz, H.
Swanson, N.
Lareu, Ricardo
Raghunath, M.
author_sort Wang, Z.
building Curtin Institutional Repository
collection Online Access
description Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with transforming growth factor (TGF)-β1 with or without SAHA. Collagen deposition, α-smooth muscle actin (α-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP (TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mononuclear cells (PBMC) and its subpopulations.SAHA abrogated TGF-β1 effects on all the fibroblast lines by preventing their transdifferentiation into α-SMA positive myofibroblasts and increased collagen deposition without inducing apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and caused hyperacetylation of α-tubulin and histone. Cytokine secretion was inhibited from PBMC and lymphocytes at nonapoptotic concentrations. Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties of SAHA, suggesting its therapeutic potential for pulmonary fibrosis.
first_indexed 2025-11-14T08:37:42Z
format Journal Article
id curtin-20.500.11937-34604
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:37:42Z
publishDate 2009
publisher European Respiratory Society
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-346042017-09-13T15:13:58Z Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis? Wang, Z. Chen, C. Finger, S. Kwajah, M. Jung, M. Schwarz, H. Swanson, N. Lareu, Ricardo Raghunath, M. suberoylanilide hydroxamic acid pulmonary fibrosis collagen Antifibrotic histone deacetylase inhibitor fibroblast Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with transforming growth factor (TGF)-β1 with or without SAHA. Collagen deposition, α-smooth muscle actin (α-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP (TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mononuclear cells (PBMC) and its subpopulations.SAHA abrogated TGF-β1 effects on all the fibroblast lines by preventing their transdifferentiation into α-SMA positive myofibroblasts and increased collagen deposition without inducing apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and caused hyperacetylation of α-tubulin and histone. Cytokine secretion was inhibited from PBMC and lymphocytes at nonapoptotic concentrations. Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties of SAHA, suggesting its therapeutic potential for pulmonary fibrosis. 2009 Journal Article http://hdl.handle.net/20.500.11937/34604 10.1183/09031936.00084808 European Respiratory Society unknown
spellingShingle suberoylanilide hydroxamic acid
pulmonary fibrosis
collagen
Antifibrotic
histone deacetylase inhibitor
fibroblast
Wang, Z.
Chen, C.
Finger, S.
Kwajah, M.
Jung, M.
Schwarz, H.
Swanson, N.
Lareu, Ricardo
Raghunath, M.
Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title_full Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title_fullStr Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title_full_unstemmed Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title_short Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
title_sort suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
topic suberoylanilide hydroxamic acid
pulmonary fibrosis
collagen
Antifibrotic
histone deacetylase inhibitor
fibroblast
url http://hdl.handle.net/20.500.11937/34604